Asset Details
Do you wish to reserve the book?
Long-Term Evaluation of Patients with Hydatidosis Treated with Benzimidazole Carbamates
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Long-Term Evaluation of Patients with Hydatidosis Treated with Benzimidazole Carbamates
Do you wish to request the book?
Long-Term Evaluation of Patients with Hydatidosis Treated with Benzimidazole Carbamates
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Long-Term Evaluation of Patients with Hydatidosis Treated with Benzimidazole Carbamates
1999
Overview
Four hundred forty-eight patients with 929 Echinococcus granulosus hydatid cysts received 3- to 6-month continuous cycles of mebendazole or albendazole treatment and underwent prolonged follow-up by clinical visits and imaging studies (range, 1–14 years) to assess the long-term outcome of treatment. Degenerative changes and relapse were assessed by imaging techniques. At the end of therapy, 74.1% of the hydatid cysts showed degenerative changes. These were more frequent in albendazole-treated than in mebendazole-treated cysts (82.2% vs. 56.1%; P < .001). During longterm follow-up, 104 cysts (22%) had degenerative changes that progressed, whereas 163 cysts (∼25%) relapsed. The percentages of relapses in the two drug-treated groups were almost the same. Relapses occurred more frequently in type II cysts of the liver. Cysts recurred most often (78.5%; P < .001) within the first 2 years after treatment ended. Further chemotherapy cycles induced degenerative changes in >90% of relapsed cysts without inducing more frequent or more severe side effects than those observed during the initial cycles.
Publisher
The University of Chicago Press,University of Chicago Press
Subject
/ Adult
/ Aged
/ Albendazole - adverse effects
/ Albendazole - therapeutic use
/ Animals
/ Anthelmintics - therapeutic use
/ Benzimidazoles - adverse effects
/ Benzimidazoles - therapeutic use
/ Biological and medical sciences
/ Carbamates - adverse effects
/ Carbamates - therapeutic use
/ Child
/ Cysts
/ Echinococcosis - diagnostic imaging
/ Echinococcosis - drug therapy
/ Echinococcosis, Hepatic - diagnostic imaging
/ Echinococcosis, Hepatic - drug therapy
/ Echinococcosis, Hepatic - pathology
/ Echinococcosis, Pulmonary - diagnostic imaging
/ Echinococcosis, Pulmonary - drug therapy
/ Echinococcosis, Pulmonary - pathology
/ Female
/ Humans
/ Hydatids
/ Imaging
/ Liver
/ Male
/ Mebendazole - adverse effects
/ Mebendazole - therapeutic use
/ Relapse
